Plethora Therapeutics

Wren Therapeutics (formerly Plethora Therapeutics) is a biopharmaceutical company pioneering a chemical kinetics-based approach to drug discovery for neurodegenerative diseases. Spun out from the University of Cambridge and Lund University, the company utilizes its proprietary Network Kinetics platform to identify small molecules that precisely target the transient molecular species responsible for protein misfolding and aggregation. Their pipeline focuses on major proteinopathies, including Parkinson's disease and Alzheimer's disease, by targeting proteins such as alpha-synuclein and amyloid-beta. Wren's unique methodology allows for the quantification of the effects of drugs on the individual steps of the aggregation process, aiming to develop highly potent and selective therapeutics. The company has established strategic collaborations with major pharmaceutical firms, including Eisai, to advance its lead programs.